Eurofins Scientific SE (EPA:ERF)
France
· Delayed Price · Currency is EUR | Market Cap | 10.51B |
| Revenue (ttm) | 7.30B |
| Net Income (ttm) | 416.10M |
| Shares Out | 175.93M |
| EPS (ttm) | 2.23 |
| PE Ratio | 26.80 |
| Forward PE | 14.30 |
| Dividend | 0.72 (1.17%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | 293,434 |
| Average Volume | 341,537 |
| Open | 60.38 |
| Previous Close | 61.54 |
| Day's Range | 59.76 - 60.76 |
| 52-Week Range | 53.34 - 74.32 |
| Beta | 0.91 |
| RSI | 33.56 |
| Earnings Date | Apr 30, 2026 |
About Eurofins Scientific SE
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product tes... [Read more]
Financial Performance
In 2025, Eurofins Scientific SE's revenue was 7.30 billion, an increase of 4.96% compared to the previous year's 6.95 billion. Earnings were 416.10 million, an increase of 16.78%.
Financial StatementsNews
Eurofins Scientific: Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF) (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). ...
Eurofins Scientific SE Earnings Call Transcript: Q1 2026
Q1 revenue growth was hampered by severe weather, but March rebounded to mid-single digits. Management maintains full-year mid-single-digit organic growth guidance and expects continued margin improvement, supported by digitalization and portfolio optimization.
Eurofins Scientific To Divest Electrical & Electronic Testing Business
(RTTNews) - Eurofins Scientific SE (EUFI.PA, ERF.PA) announced the signing of an agreement to divest its Electrical & Electronic Testing business, or MET Labs, to UL Solutions for an enterprise value ...
ULS Acquires Eurofins Scientific's Electrical and Electronics Business
ULS Acquires Eurofins Scientific's Electrical and Electronics Business
Eurofins Scientific SE: Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification ...
Eurofins Scientific: Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing F...
Eurofins Scientific : Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification ...
Eurofins Scientific SE Earnings Call Transcript: Q4 2025
2025 saw strong margin and EPS growth, with accelerating organic growth and robust free cash flow. Major investments in IT and site ownership are nearing completion, supporting future efficiency and expansion. Share buybacks and prudent capital allocation remain priorities.
Eurofins Scientific SE: Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification...
Eurofins Scientific SE Earnings Call Transcript: Q3 2025
Progress on network expansion and digitalization is on track, with margin improvements and strong cash flow expected. BioPharma and Life segments are performing well, while genomics and agroscience are stabilizing. FX headwinds are minor, and buybacks remain a capital allocation priority.
Eurofins Scientific SE Earnings Call Transcript: Q2 2025
H1 2025 saw strong revenue, margin, and EPS growth, with mature business margins at target levels and ongoing investments in infrastructure and digitalization. Management remains confident in achieving 2027 targets, with biopharma recovery and further efficiency gains expected.
Eurofins Scientific SE Earnings Call Transcript: Q1 2025
Q1 2025 delivered strong organic growth in food and environmental testing, with U.S. weather disruptions expected to be offset later in the year. Major Spanish acquisition and IT investments are underway, while guidance and capital allocation priorities remain unchanged.
Eurofins Scientific SE Earnings Call Transcript: Q4 2024
FY 2024 saw strong revenue and margin growth, with mature businesses nearing target profitability and free cash flow up 69%. While BioPharma and Agroscience were soft, long-term growth and margin targets are reaffirmed, and major investments are nearing completion.
Eurofins Scientific SE Earnings Call Transcript: Q3 2024
Q3 saw softer growth due to BioPharma and Agroscience declines, but profitability and margins remained strong. Share buybacks increased as M&A slowed, and 2025 growth targets are reaffirmed, with BioPharma recovery expected in H2.
Eurofins Scientific SE Earnings Call Transcript: Q2 2024
Strong H1 results with 6.5% revenue growth, 21% EBITDA increase, and 220 bps margin improvement, driven by operational efficiencies and digitalization. Biopharma softness seen as temporary; robust cash flow and balance sheet support continued investment and share buybacks.
Eurofins Scientific announces the acquisition of Labormar, further expanding its presence in Latin America and its Food and Feed, Environmental, Cosmetic and Pharmacological testing offering in Colombia
BARRANQUILLA, Colombia--(BUSINESS WIRE)--The Eurofins network of companies, a world leader in food, environment, pharmaceutical and cosmetic product testing, announces the completion of the acquisitio...
Eurofins Scientific's stock drops on allegations from short-seller Muddy Waters
Eurofins Scientific shares plunged on Monday after Muddy Waters Research said in a report it had started shorting the laboratory-services company, alleging founder and Chief Executive Gilles Martin ha...
Eurofins Scientific SE Earnings Call Transcript: Q1 2024
Eurofins Scientific SE Earnings Call Transcript: Q4 2023
Eurofins Scientific Announces the Acquisition of Quasfar, Establishing a Presence in Colombia and Expanding the Presence of Eurofins Laboratories in Latin America
LUXEMBOURG--(BUSINESS WIRE)--The Eurofins network of companies, the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced m...
Eurofins Scientific Announces the Acquisition of Labor 3, Further Expanding Its Offering to the Food and Feed Market in Brazil and the Presence of Eurofins Laboratories in Latin America
LUXEMBOURG--(BUSINESS WIRE)--The Eurofins network of companies, the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced m...